Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.
Compounded GLP-1 Guidepricing database · evidence ledger

Safety, regulation, and how to verify what you're buying

Compounded semaglutide and tirzepatide are prepared by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities. Neither pathway makes the product FDA approved: FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Consumers can reduce risk by confirming the dispensing pharmacy's state license, distinguishing registration from approval, checking FDA warning-letter and recall databases, and reviewing beyond-use dates on multi-month shipments — steps this guide walks through with primary-source links.

503A vs 503B, in plain terms

503A compounding pharmacy

State-licensed pharmacy compounding for individual patients pursuant to a prescription. Overseen primarily by state boards of pharmacy. Not FDA registered as a manufacturer; products are not FDA approved.

503B outsourcing facility

FDA-registered facility that may compound larger batches under cGMP and is subject to FDA inspection. Registration is a facility status — it is not approval of any product the facility makes.

Never treat "FDA-registered" as "FDA-approved," and never treat a state pharmacy license as federal product approval. No pharmacy is "FDA approved" or "FDA licensed."

Verify a pharmacy yourself

Scope and definitions

This guide covers consumer-facing safety and regulation for compounded semaglutide and tirzepatide obtained through telehealth: what "compounded" means, how the two pharmacy pathways are overseen, the risks specific to compounded products, and the checks a non-clinician can perform. A few terms recur. Compounding is the pharmacy preparation of a medication for a patient, distinct from manufacturing an approved drug. A 503A pharmacy compounds patient-specific prescriptions under state oversight; a 503B outsourcing facility registers with FDA and may batch-compound under federal manufacturing standards. Beyond-use date is the pharmacy-assigned date after which a compounded preparation shouldn't be used. None of these preparations is FDA approved, and nothing in this guide is medical advice.

Where the real risks concentrate

The safety questions specific to compounded GLP-1 medications are different from the well-characterized side effects of the approved drugs. Four risk clusters matter most, and none is captured by a marketing page's reassurances. Formulation variability: because no premarket review standardizes a compounded product, potency, concentration, sterility, and added ingredients vary by pharmacy and batch — two vials labeled "semaglutide" from different pharmacies are not guaranteed to be the same preparation. Concentration-driven dosing errors: when concentration changes between shipments, the same prescribed milligram dose occupies a different number of insulin-syringe units, and mis-reading units for milligrams is a documented source of overdose in this category. Salt-form ingredients: semaglutide sodium and semaglutide acetate are salt forms that are not interchangeable with the semaglutide base used in approved products, and their safety and potency in humans are not established. Cold-chain and beyond-use failures: injectable peptides degrade, and a warm-arriving or past-beyond-use shipment can be sub-potent or unsafe.

Each risk has a consumer-side mitigation, which is the practical point of this page: verify the pharmacy, read every label against the last one, question any concentration change with the prescriber before injecting, and refuse shipments whose beyond-use dates don't cover their intended use window. None of these require clinical training — they require knowing to ask.

What the regulatory record shows

Regulators have documented category-level concerns rather than merely theoretical ones. FDA has repeatedly warned about dosing errors with compounded semaglutide, including errors traced to patients measuring doses in units on syringes that didn't match the product's concentration, and about products using unapproved salt forms. Poison-control centers reported a sharp rise in semaglutide-related calls during the peak compounding period. FDA has also pursued enforcement against misleading telehealth marketing of compounded GLP-1 drugs, and in a proposal dated April 30, 2026 addressed semaglutide, tirzepatide, and liraglutide in relation to the 503B bulks list. With the underlying shortages resolved, the legal basis for mass-marketed compounding narrowed substantially, and compounded access now generally depends on documented patient-specific clinical need rather than broad availability. Specific enforcement items, adverse-event totals, and the current status of that proposal are tracked in our newsroom and publish only after primary-source verification — this page states the pattern, not unverified counts.

What the published evidence does and doesn't cover

It's important to separate two bodies of evidence that marketing routinely blurs. The large trials — STEP and SUSTAIN for semaglutide, SURMOUNT and SURPASS for tirzepatide — studied specific FDA-approved products at defined doses, and they establish efficacy and a safety profile for those products. There is no comparable trial base establishing that any particular compounded preparation matches those results, because compounded products aren't studied that way; their quality rests on the individual pharmacy. Real-world data on compounded GLP-1 use is accumulating but is largely observational, often provider-sponsored, and subject to the usual limits of uncontrolled cohorts. The honest position is that the approved-product evidence is strong and specific, the compounded-product evidence is thin and formulation-dependent, and the two cannot be merged — a point our research library preserves study by study. Anyone told that a compounded product "has the same clinical evidence" as Wegovy or Zepbound is being misinformed.

Telehealth red flags

Some warning signs reliably separate cautious providers from reckless ones. Treat these as reasons to slow down or walk away: a provider that won't name the dispensing pharmacy before payment; any claim that a compounded product or a pharmacy is "FDA approved" or "FDA licensed"; "research use only" or "not for human consumption" framing on a product marketed for weight loss; no requirement for a prescription or medical review; prices dramatically below the roughly $99/month legitimate floor, which raise questions about API sourcing and oversight; pressure tactics like countdown timers or stock-scarcity claims; and marketing that borrows the approved products' trial results (15%, 20% weight loss) as if they were the compounded product's own outcomes. A single flag isn't proof of harm, but several together describe a seller optimizing for conversion over safety.

What to verify before you buy

The pre-purchase checklist is short and non-clinical. Confirm the specific dispensing pharmacy and verify its state license and — for your state — its nonresident license, using the four-step workflow. Confirm the product's active ingredient is the base form, not an unproven salt form, and ask which it is in writing. Confirm the concentration and whether it can change between shipments, since that governs your unit measurements. Confirm the beyond-use dating practice on multi-month plans. Confirm that a licensed prescriber reviews your history and remains reachable for side-effect questions. And price the FDA-approved alternatives you may have access to, which carry premarket-reviewed manufacturing that no compounded product has.

Counterfeits and where they come from

Distinct from legitimate compounding is the outright counterfeit market, which grew alongside GLP-1 demand. Counterfeit semaglutide — products sold as semaglutide that may contain the wrong ingredient, the wrong amount, or nothing active at all — has been documented entering supply chains, typically through channels outside the licensed pharmacy system: unsolicited online sellers, social-media marketplaces, "research chemical" vendors, and international sites that ship without a prescription. The defining features of these channels are the red flags to avoid: no prescription required, no licensed pharmacy, prices far below even the compounded market, "research use only" labeling on a product marketed for weight loss, and payment or shipping arrangements designed to evade oversight. A legitimate compounded product comes from a state-licensed pharmacy pursuant to a prescription; a product that skips those steps isn't a cheaper version of the same thing, it's a different and unregulated risk.

If something goes wrong

Emergency guidance, stated plainly: signs of a severe allergic reaction (difficulty breathing, swelling of the face or throat, hives), severe or persistent abdominal pain (a possible sign of pancreatitis), or symptoms of significant dehydration from prolonged vomiting warrant urgent medical care — call your local emergency number, not the telehealth provider. For a suspected dosing error, contact a poison-control center and your prescriber immediately. For a shipment that arrives warm, damaged, or past its beyond-use date, do not use it; document it with photos and contact the pharmacy and provider. Suspected quality problems can also be reported to FDA's MedWatch program, which is how category-level safety signals get detected. Keep the product, packaging, and label — they carry the concentration and pharmacy information any clinician will need.

Limitations of this guide

This page describes category-level risks and consumer-side checks; it is not medical advice, does not diagnose, and cannot anticipate an individual's contraindications or interactions. Adverse-event and enforcement specifics change and are verified separately before we publish counts or name entities. The absence of a warning here about a particular provider or pharmacy is not an endorsement — it usually means verification is incomplete. Whether a compounded product is appropriate for you at all is a decision only a licensed prescriber who knows your history can make.

Frequently asked questions

Is compounded semaglutide safe?

There's no single answer, because "compounded semaglutide" isn't one standardized product — safety depends on the specific pharmacy's quality, the formulation, correct dosing, and your individual health. Unlike the approved products, no premarket FDA review of safety, effectiveness, or quality stands behind it. That doesn't make every preparation unsafe, but it shifts the burden of verification onto you and your prescriber. Confirm the pharmacy, the ingredient form, and the concentration, and keep a licensed clinician involved.

What is a semaglutide salt form and why does it matter?

Semaglutide sodium and semaglutide acetate are salt forms of the molecule. FDA has flagged that these are not the same as the semaglutide base in approved products, and their safety and effectiveness in humans aren't established. Some compounders have used salt forms; you can't tell from a label that says only "semaglutide." Ask the pharmacy, in writing, which form your product uses.

Why are dosing errors a specific risk here?

Injectable compounded GLP-1s come in varying concentrations, and doses are drawn in "units" on an insulin syringe. Units measure volume, not drug amount, so the correct unit count for a given prescribed dose changes when concentration changes. Patients who apply an old unit count to a new, differently concentrated vial can significantly overdose. Always re-read the label each shipment and confirm any concentration change with your prescriber before injecting.

My shipment arrived warm — can I use it?

Don't use it until you've confirmed it's safe. Many compounded GLP-1 products require refrigeration, and peptides can degrade with heat exposure. Photograph the package and contents, and contact the pharmacy and provider for guidance and replacement. Don't assume warm equals ruined or warm equals fine — the pharmacy's storage instructions and its judgment on that specific product govern.

How do I know if a telehealth provider is legitimate?

Legitimacy shows in verifiable specifics: a named dispensing pharmacy you can check against a state board, a required medical review by a licensed prescriber, honest FDA-status language, no "research use" framing, and prices that aren't implausibly low. Certifications like LegitScript are a positive signal but should be confirmed in the certifier's registry rather than taken from the provider's own claim. Our verification guide walks through the checks.

What should I do if I think I received a counterfeit?

Stop using it, keep the product and packaging, and contact your prescriber and a poison-control center if you've taken any. Report it to FDA's MedWatch program, which tracks these signals. Counterfeits typically come from channels outside the licensed system — no prescription, no named pharmacy, implausibly low prices — so if you bought through such a channel, treat the product as suspect until verified. A legitimate compounded product comes from a state-licensed pharmacy pursuant to a prescription.

Are the serious warnings on the approved drugs relevant to compounded versions?

Yes. The class-wide serious warnings and contraindications that apply to approved semaglutide and tirzepatide — including the boxed thyroid-tumor warning and cautions around pancreatitis, gallbladder disease, and certain personal or family medical histories — apply to whatever active drug a compounded product delivers. Compounding changes the manufacturing and oversight, not the underlying pharmacology. A prescriber should review your history against these warnings exactly as they would for the approved product.